First Time Loading...

Interpace Biosciences Inc
OTC:IDXG

Watchlist Manager
Interpace Biosciences Inc Logo
Interpace Biosciences Inc
OTC:IDXG
Watchlist
Price: 1.43 USD -1.38% Market Closed
Updated: May 16, 2024

Gross Margin
Interpace Biosciences Inc

59.4%
Current
53%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.4%
=
Gross Profit
23.9m
/
Revenue
40.2m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Interpace Biosciences Inc
OTC:IDXG
6.2m USD
59%
US
Cigna Group
XMUN:CGN
91.5B EUR
12%
US
Cigna Corp
NYSE:CI
97.5B USD
12%
US
CVS Health Corp
NYSE:CVS
70.4B USD
15%
US
Laboratory Corporation of America Holdings
NYSE:LH
18B USD
28%
DE
Fresenius SE & Co KGaA
XETRA:FRE
16.2B EUR
23%
US
Quest Diagnostics Inc
NYSE:DGX
15.6B USD
33%
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
12.3B EUR
25%
DE
Fresenius Medical Care AG
XMUN:FME
12B EUR
25%
US
DaVita Inc
NYSE:DVA
12.1B USD
32%
US
Oak Street Health Inc
NYSE:OSH
9.5B USD
4%
Interpace Biosciences Inc
OTC:IDXG
Country US
Market Cap 6.2m USD
Gross Margin
59%
C
Cigna Group
XMUN:CGN
Country US
Market Cap 91.5B EUR
Gross Margin
12%
Cigna Corp
NYSE:CI
Country US
Market Cap 97.5B USD
Gross Margin
12%
CVS Health Corp
NYSE:CVS
Country US
Market Cap 70.4B USD
Gross Margin
15%
Laboratory Corporation of America Holdings
NYSE:LH
Country US
Market Cap 18B USD
Gross Margin
28%
Fresenius SE & Co KGaA
XETRA:FRE
Country DE
Market Cap 16.2B EUR
Gross Margin
23%
Quest Diagnostics Inc
NYSE:DGX
Country US
Market Cap 15.6B USD
Gross Margin
33%
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Country DE
Market Cap 12.3B EUR
Gross Margin
25%
Fresenius Medical Care AG
XMUN:FME
Country DE
Market Cap 12B EUR
Gross Margin
25%
DaVita Inc
NYSE:DVA
Country US
Market Cap 12.1B USD
Gross Margin
32%
Oak Street Health Inc
NYSE:OSH
Country US
Market Cap 9.5B USD
Gross Margin
4%

Profitability Report

View the profitability report to see the full profitability analysis for Interpace Biosciences Inc.

Full Profitability Report

See Also

Summary
IDXG intrinsic value, competitors valuation, and company profile.
DCF Valuation
IDXG stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IDXG stock valuation using valuation multiples.
Wall Street Estimates
IDXG price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IDXG stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
59.4%
=
Gross Profit
23.9m
/
Revenue
40.2m
What is the Gross Margin of Interpace Biosciences Inc?

Based on Interpace Biosciences Inc's most recent financial statements, the company has Gross Margin of 59.4%.

ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.